Literature DB >> 17615094

No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease.

Katharina Buerger, Irina Alafuzoff, Michael Ewers, Tuula Pirttilä, Raymond Zinkowski, Harald Hampel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17615094     DOI： 10.1093/brain/awm140

Source DB:  PubMed          Journal:  Brain        ISSN： 0006-8950            Impact factor:   13.501


× No keyword cloud information.
  28 in total

Review 1.  Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers.

Authors:  Christiane Reitz; Richard Mayeux
Journal:  Biochem Pharmacol       Date:  2014-01-04       Impact factor: 5.858

2.  Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia.

Authors:  Christoph Laske; Elke Stransky; Andreas Fritsche; Gerhard W Eschweiler; Thomas Leyhe
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-09-19       Impact factor: 5.270

3.  Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network.

Authors:  Hideyuki Takahashi; Zoe A Klein; Sarah M Bhagat; Adam C Kaufman; Mikhail A Kostylev; Tsuneya Ikezu; Stephen M Strittmatter
Journal:  Acta Neuropathol       Date:  2017-01-09       Impact factor: 17.088

4.  Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer's disease.

Authors:  Joana R F Santos; Chris Bauer; Johannes Schuchhardt; Dirk Wedekind; Katharina Waniek; Ingolf Lachmann; Jens Wiltfang; Jonathan Vogelgsang
Journal:  J Neural Transm (Vienna)       Date:  2019-02-14       Impact factor: 3.575

5.  Cerebrospinal fluid biomarkers in clinical subtypes of early-onset Alzheimer's disease.

Authors:  Edmond Teng; Tritia R Yamasaki; Michelle Tran; Julia J Hsiao; David L Sultzer; Mario F Mendez
Journal:  Dement Geriatr Cogn Disord       Date:  2013-12-31       Impact factor: 2.959

Review 6.  CSF biomarkers for amyloid and tau pathology in Alzheimer's disease.

Authors:  Hanna Rosenmann
Journal:  J Mol Neurosci       Date:  2011-11-05       Impact factor: 3.444

7.  Cerebrospinal fluid biomarkers for dementia with lewy bodies.

Authors:  Elizabeta B Mukaetova-Ladinska; Rachael Monteith; Elaine K Perry
Journal:  Int J Alzheimers Dis       Date:  2010-10-17

8.  Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study.

Authors:  Felix Bermejo-Pareja; Desiree Antequera; Teo Vargas; Jose A Molina; Eva Carro
Journal:  BMC Neurol       Date:  2010-11-03       Impact factor: 2.474

Review 9.  Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease.

Authors:  Christopher D Aluise; Renã A Sowell; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2008-08-07

10.  The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease.

Authors:  Lidia Glodzik-Sobanska; Elizabeth Pirraglia; Miroslaw Brys; Susan de Santi; Lisa Mosconi; Kenneth E Rich; Remigiusz Switalski; Leslie Saint Louis; Martin J Sadowski; Frank Martiniuk; Pankaj Mehta; Domenico Pratico; Raymond P Zinkowski; Kaj Blennow; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2007-10-24       Impact factor: 4.673
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.